Pooled estimates of clinical events in studies comparing DOACs vs warfarin in patients with concomitant CKD and AF by CKD stages in non-RCT studies
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test, P value . | Higgins I2, % . | ||
| Overall bleeds (non-RCTs) | ||||||
| CKD stages 1-2 | 37 718 | 0.84 | 0.54-1.30 | .43 | <.01 | 93 |
| CKD stages 3 | 43 669 | 0.44 | 0.22-0.88 | .02 | <.01 | 97 |
| CKD stages 4-5 | 5 906 | 0.66 | 0.51-0.86 | <.01 | .48 | 0 |
| CKD dialysis | 30 848 | 0.58 | 0.47-0.72 | <.01 | .18 | 39 |
| Stroke incidence (non-RCTs) | ||||||
| CKD stages 1-2 | 24 060 | 0.96 | 0.78-1.17 | .67 | .34 | 0 |
| CKD stages 3 | 11 157 | 0.63 | 0.26-1.52 | .31 | <.01 | 86 |
| CKD stages 4-5 | 7 171 | 0.75 | 0.49-1.17 | .20 | .08 | 56 |
| CKD dialysis | 18 945 | 0.90 | 0.33-1.07 | .83 | .04 | 76 |
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test, P value . | Higgins I2, % . | ||
| Overall bleeds (non-RCTs) | ||||||
| CKD stages 1-2 | 37 718 | 0.84 | 0.54-1.30 | .43 | <.01 | 93 |
| CKD stages 3 | 43 669 | 0.44 | 0.22-0.88 | .02 | <.01 | 97 |
| CKD stages 4-5 | 5 906 | 0.66 | 0.51-0.86 | <.01 | .48 | 0 |
| CKD dialysis | 30 848 | 0.58 | 0.47-0.72 | <.01 | .18 | 39 |
| Stroke incidence (non-RCTs) | ||||||
| CKD stages 1-2 | 24 060 | 0.96 | 0.78-1.17 | .67 | .34 | 0 |
| CKD stages 3 | 11 157 | 0.63 | 0.26-1.52 | .31 | <.01 | 86 |
| CKD stages 4-5 | 7 171 | 0.75 | 0.49-1.17 | .20 | .08 | 56 |
| CKD dialysis | 18 945 | 0.90 | 0.33-1.07 | .83 | .04 | 76 |
The results represent a pooled estimate for all DOACs (apixaban, edoxaban, and rivaroxaban).